INMDNasdaqElectromedical & Electrotherapeutic ApparatusUS GAAP · USD

InMode Ltd.

InMode Ltd. develops, manufactures, and markets minimally invasive medical devices built around radiofrequency technology. Its systems are used across aesthetic and specialty medical procedures, with customers in plastic surgery, dermatology, gynecology, otolaryngology, and ophthalmology markets in the United States, Israel, Europe, and other international regions.

Liikevaihto370milj. USD
−6,2 %v/v
Liikevoitto (EBIT)85,4milj. USD
−24,1 %v/v
EBIT-marginaali23,0%
−5,5 %-yks.v/v
Nettotulos93,8milj. USD
−48,2 %v/v
Vapaa kassavirta84,3milj. USD
−36,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

0100200300400500milj. USD2020: 206 milj. USD2020: EBIT 73 milj. USD20202021: 358 milj. USD2021: EBIT 167 milj. USD20212022: 454 milj. USD2022: EBIT 198 milj. USD20222023: 492 milj. USD2023: EBIT 196 milj. USD20232024: 395 milj. USD2024: EBIT 113 milj. USD20242025: 370 milj. USD2025: EBIT 85 milj. USD202537085
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Aesthetic procedure platforms45 %

RF-based devices used in plastic surgery and aesthetic medicine procedures.

Dermatology systems25 %

Energy-based devices used by dermatology practices for skin and body treatments.

Gynecology devices15 %

Systems and tools used in minimally invasive gynecological procedures.

ENT and ophthalmology devices10 %

Specialty medical devices used in otolaryngology and ophthalmology applications.

Accessories and consumables5 %

Procedure-related handpieces, disposables, and supporting items sold with devices.

Tuotteet

Raportoitu · osuus liikevaihdosta
78,0%22,0%FY2025100 %
  • Capital Equipment78,0 %
  • Consumables and Service Revenues22,0 %

Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

InMode sells primarily to medical professionals and clinics that perform elective or specialty procedures using energy-based technology. The core users are plastic surgeons, dermatologists, gynecologists, ENT specialists, and ophthalmologists, who buy the systems to broaden procedure offerings and improve treatment workflows. Purchases are typically made by outpatient practices, clinics, and medical groups that invest in capital equipment tied to procedure volume and patient demand.

Plastic surgery practices

Buy RF platforms for aesthetic and minimally invasive body procedures.

Dermatology clinics

Buy devices for skin tightening, contouring, and related treatments.

Gynecology practices

Buy procedure systems for minimally invasive women's health applications.

ENT and ophthalmology practices

Buy specialty devices for selected surgical and procedural uses.

Medical groups and outpatient centers

Buy equipment to support procedure throughput and service expansion.

Strategia

InMode’s strategy centers on expanding adoption of its RF platforms across aesthetic and specialty medical practices while strengthening commercial execution in North America and Europe. The company also emphasizes capital allocation discipline, including share repurchases, while continuing to invest in sales and management coverage that supports procedure adoption and recurring customer relationships.

Commercial expansion in North AmericaLyhyt aikaväli

The U.S. is a key market and recent commentary highlighted its contribution to growth.

European market executionLyhyt aikaväli

Europe is a meaningful region for aesthetic devices and requires local commercial coverage.

Broaden procedure adoptionKeskipitkä aikaväli

More procedure use increases installed-base value and repeat commercial opportunity.

Capital allocation disciplineLyhyt aikaväli

Repurchases can return cash when operations generate surplus liquidity.

Maantiede

2025

InMode is a global business with development and operating roots in Israel and commercial exposure across the United States, Europe, and other international markets. The company’s reports specifically note that the U.S. contributed meaningfully to recent growth, while management continues to build out sales and management coverage in North America and Europe. Its geographic mix matters because demand for elective medical procedures, reimbursement norms, and distributor coverage can vary significantly by region.

USA60 %
Europe24 %
Asia15 %
Israel1,0 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

InMode is exposed to discretionary demand for aesthetic and elective procedures, which can soften when macroeconomic conditions weaken or patient spending is deferred. The company also faces execution risk in geographically dispersed sales organizations, competitive pressure in energy-based medical devices, and event risk tied to its ongoing regional exposure in Israel. Product development, regulatory requirements, and reliance on physician adoption also shape the risk profile.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Discretionary demand for aesthetic procedures1Sales force execution in key regions2Competitive pressure in RF medical devices3Geopolitical exposure in Israel4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Discretionary demand for aesthetic proceduresVaikutus: KorkeaTodennäköisyys: Korkea

    Customers can delay elective purchases and procedure utilization when economic conditions weaken.

    Kohdistuu: Aesthetic and plastic surgery markets

  2. Sales force execution in key regionsVaikutus: KeskitasoTodennäköisyys: Korkea

    Revenue depends on effective physician coverage, training, and local account development.

    Kohdistuu: North America and Europe

  3. Competitive pressure in RF medical devicesVaikutus: KeskitasoTodennäköisyys: Korkea

    Alternative energy-based platforms and new entrants can affect share and pricing.

    Kohdistuu: Aesthetic and specialty medical devices

  4. Geopolitical exposure in IsraelVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The company is headquartered and operates from Israel, so conflict can affect operations and sentiment.

    Kohdistuu: Israel

Kirjanpito

Harkinnanvaraiset erät
Non-GAAP exclusions

Management excludes share-based compensation and special committee costs, affecting comparison to GAAP earnings.

Vaikutus: Affects operating margin and EPS presentation

Revenue timing and quarterly seasonality

Device shipments and customer purchasing patterns can vary by quarter, affecting revenue comparability.

Vaikutus: Impacts quarterly growth rates and margin trends

Income tax valuation allowance

The company disclosed a U.S. deferred tax asset valuation allowance release based on future profitability expectations.

Vaikutus: Can materially affect tax expense and net income

Share repurchase accounting

Repurchases reduce shares outstanding and can change EPS even without changing operating performance.

Vaikutus: Affects diluted EPS and equity balances

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 28.9.2026

InMode Ltd. (INMD) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo